Table 2.

Clinical presentation by primary diagnosis and primary therapy


Clinical feature

No. patients

t-MDS→unknown (%)

t-MDS (%)

t-MDS→t-AML (%)

t-AML (%)
Primary diagnosis*      
No malignancy   18   6 (33)   3 (17)   5 (28)   4 (22)  
Hematologic malignancy   171   33 (19)   44 (26)   61 (36)   33 (19)  
Hodgkin disease   77   14 (18)   13 (17)   33 (43)   17 (22)  
Non-Hodgkin lymphoma   70   12 (17)   26 (37)   22 (31)   10 (14)  
Myeloma   23   7 (30)   5 (21)   6 (26)   5 (22)  
Other   1   0   0   0   1 (100)  
Solid tumor   117   15 (13)   25 (21)   32 (27)   45 (38)  
Breast   32   4 (13)   2 (6)   14 (44)   12 (38)  
Ovary   15   1 (7)   2 (13)   3 (20)   9 (60)  
Prostate   13   2 (15)   5 (38)   0   6 (46)  
Lung   9   0   2 (22)   2 (22)   5 (56)  
Cervix   7   1 (14)   3 (43)   1 (14)   2 (29)  
Other   41   7 (17)   11 (27)   12 (29)   11 (27)  
Totals   306   54 (18)   72 (24)   98 (32)   82 (27)  
Primary therapy      
CT only   121   31 (26)   26 (21)   36 (30)   28 (23)  
RT only   43   4 (9)   13 (30)   11 (26)   15 (35)  
CMT
 
139
 
19 (14)
 
33 (24)
 
51 (37)
 
36 (26)
 

Clinical feature

No. patients

t-MDS→unknown (%)

t-MDS (%)

t-MDS→t-AML (%)

t-AML (%)
Primary diagnosis*      
No malignancy   18   6 (33)   3 (17)   5 (28)   4 (22)  
Hematologic malignancy   171   33 (19)   44 (26)   61 (36)   33 (19)  
Hodgkin disease   77   14 (18)   13 (17)   33 (43)   17 (22)  
Non-Hodgkin lymphoma   70   12 (17)   26 (37)   22 (31)   10 (14)  
Myeloma   23   7 (30)   5 (21)   6 (26)   5 (22)  
Other   1   0   0   0   1 (100)  
Solid tumor   117   15 (13)   25 (21)   32 (27)   45 (38)  
Breast   32   4 (13)   2 (6)   14 (44)   12 (38)  
Ovary   15   1 (7)   2 (13)   3 (20)   9 (60)  
Prostate   13   2 (15)   5 (38)   0   6 (46)  
Lung   9   0   2 (22)   2 (22)   5 (56)  
Cervix   7   1 (14)   3 (43)   1 (14)   2 (29)  
Other   41   7 (17)   11 (27)   12 (29)   11 (27)  
Totals   306   54 (18)   72 (24)   98 (32)   82 (27)  
Primary therapy      
CT only   121   31 (26)   26 (21)   36 (30)   28 (23)  
RT only   43   4 (9)   13 (30)   11 (26)   15 (35)  
CMT
 
139
 
19 (14)
 
33 (24)
 
51 (37)
 
36 (26)
 

t-MDS→unknown indicates patients with t-MDS for whom no further follow-up data were available regarding progression to t-AML before death.

*

Fisher exact test for the major categories of no malignancy, hematologic malignancy, and solid tumor (3 × 4 contingency table); P = .011.

P = .07.

Close Modal

or Create an Account

Close Modal
Close Modal